Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 in preterm versus term infants
2009-017332-41Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Serotype-specific IgG responder rate after infant series. Started May 2010; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2009-017332-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017332-41.